Evidence map›Paper›PMID 35888751›Full record

ArticleMetabolites2022

Quercetin Decreases Corneal Haze In Vivo and Influences Gene Expression of TGF-Beta Mediators In Vitro.

Tina B McKay, Pouriska B Kivanany, Sarah E Nicholas, Okhil K Nag, Michael H Elliott, W Matthew Petroll, Dimitrios Karamichos

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Tina B McKayDepartment of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Pouriska B KivananyDepartment of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Sarah E NicholasNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Okhil K NagDepartment of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0003-3371-1223
Michael H ElliottDepartment of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0002-2289-8718
W Matthew PetrollDepartment of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Dimitrios KaramichosNorth Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.ORCID 0000-0002-8761-3824
Dean McGee Eye Institute · USThe University of Texas Southwestern Medical Center · USUniversity of North Texas · USUniversity of Oklahoma Health Sciences Center · US

Funding

P30-CENTER CORE GRANT FOR VISION RESEARCHP30EY021725 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Michelle C Callegan, MICHAEL H ELLIOTT · 2011 to 2026
$10.5M
Assessment of Corneal Fibroblast Biomechanical BehaviorR01EY013322 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI PETROLL, W MATTHEW · 2001 to 2025
$9.0M
Stem Cell, Organoid and Cell Phenotyping ModuleP30EY030413 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI W MATTHEW PETROLL · 2019 to 2026
$5.9M
Regulation of Corneal Keratocyte Differentiation through the Integration of Biochemical, Biomechanical and Topographic CuesR01EY030190 · NEI · UNIVERSITY OF TEXAS DALLAS · PI SCHMIDTKE, DAVID W · 2019 to 2024
$1.9M
NEI NIH HHS P30 EY021725NEI NIH HHS P30 EY030413NEI NIH HHS R01 EY013322NEI NIH HHS R01 EY030190NIH HHS EY013322NIH HHS EY021725NIH HHS EY030190
6 · The paper itself

Abstract

We have previously reported the flavonoid, quercetin, as a metabolic regulator and inhibitor of myofibroblast differentiation in vitro. Our current study evaluated the effects of topical application of quercetin on corneal scar development using two different animal models followed by RNA analysis in vitro. Wild-type C57BL/6J mice were anesthetized and the corneal epithelium and stroma were manually debrided, followed by quercetin (0.5, 1, 5, or 50 mM) or vehicle application. Corneal scarring was assessed for 3 weeks by slit lamp imaging and clinically scored. In a separate animal study, six New Zealand White rabbits underwent lamellar keratectomy surgery, followed by treatment with 5 mM quercetin or vehicle twice daily for three days. Stromal backscattering was assessed at week 3 by in vivo confocal microscopy. In mice, a single dose of 5 mM quercetin reduced corneal scar formation. In rabbits, stromal backscattering was substantially lower in two out of three animals in the quercetin-treated group. In vitro studies of human corneal fibroblasts showed that quercetin modulated select factors of the transforming growth factor-β (TGF-β) signaling pathway. These results provide evidence that quercetin may inhibit corneal scarring. Further studies in a larger cohort are required to validate the efficacy and safety of quercetin for clinical applications.

Indexed as

antifibroticcorneal debridementcorneal wound healingflavonoidkeratectomyquercetintransforming growth factor-beta

Identifiers

PMID35888751
PMCPMC9318747
OpenAlexW4284897312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.